MediPrint™ Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead A
Company Also Announces Move into New San Diego HeadquartersSAN DIEGO--(BUSINESS WIRE)--Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has initiated its SIGHT-2 dose-finding Phase 2b study for its proprietary...
Source: pharmiweb.com